Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lexaria Bioscience (NASDAQ: LEXX) Announces $4.7M Warrant Exercise Agreement Investor Brand Network - Thu May 2, 8:56AM CDT

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing...

LEXX : 3.25 (+3.83%)
Lexaria Bioscience (NASDAQ: LEXX) Marks GLP-1 Study Milestone with Ethics Review Board Approval Investor Brand Network - Tue Apr 23, 10:03AM CDT

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board. The potential...

LEXX : 3.25 (+3.83%)
Lexaria (NASDAQ: LEXX) Grows Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies Investor Brand Network - Wed Apr 17, 9:22AM CDT

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally...

LEXX : 3.25 (+3.83%)
Lexaria Bioscience (NASDAQ: LEXX) Bolsters C-Suite with New CFO Appointment Investor Brand Network - Fri Apr 12, 9:24AM CDT

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the appointment of Nelson Cabatuan, CPA, as its new Chief Financial Officer (“CFO”). Nelson will...

LEXX : 3.25 (+3.83%)
Lexaria Bioscience (NASDAQ: LEXX) Focusing on GLP-1 Applications of DehydraTECH(TM) Investor Brand Network - Mon Apr 1, 9:37AM CDT

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM)...

LEXXW : 1.0994 (-8.38%)
LEXX : 3.25 (+3.83%)
Lexaria (NASDAQ: LEXX) Hires Research Organization to Perform GLP-1 Human Pilot Study Investor Brand Network - Tue Mar 26, 9:26AM CDT

At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar...

LEXX : 3.25 (+3.83%)
Lexaria (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational Investor Brand Network - Mon Mar 25, 9:17AM CDT

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on...

LEXX : 3.25 (+3.83%)
LEXXW : 1.0994 (-8.38%)
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss Investor Brand Network - Fri Mar 22, 9:40AM CDT

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency...

LEXX : 3.25 (+3.83%)
Lexaria to Present at The LD Micro Invitational XIV Newsfile - Thu Mar 21, 8:24AM CDT

Kelowna, British Columbia--(Newsfile Corp. - March 21, 2024) - Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces...

LEXX : 3.25 (+3.83%)
Lexaria (NASDAQ: LEXX) Marks 2024 Milestone with FDA Clearance for Planned U.S. Phase 1b Hypertension Trial Investor Brand Network - Tue Mar 19, 9:01AM CDT

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with...

LEXX : 3.25 (+3.83%)

Barchart Exclusives

Will This EV Stock Burn Short Sellers Like Tesla Did With Its Q1 Earnings Report? Barchart - 40 minutes ago
Rivian will release its Q1 earnings after the bell this Tuesday, May 7. The setup for the EV startup looks good heading into the release, which could set the stage for a post-earnings rebound like we saw with Tesla. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot